Kristen L Benninger1,2, Jessica Purnell1, Sara Conroy3,4, Kenneth Jackson3,4, Nancy Batterson1,2, Mary Lauren Neel1,2, Mark E Hester2,5, Nathalie L Maitre6. 1. Center for Perinatal Research, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA. 2. Department of Pediatrics, The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, Columbus, OH, USA. 3. Biostatistics Core, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA. 4. Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 5. The Steve and Cindy Rasmussen Institute for Genomic Medicine, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA. 6. Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Abstract
AIM: To determine whether infants with intrauterine drug exposure (IUDE) are similarly at risk for cerebral palsy (CP) as other high-risk populations, whether CP classification differs based on IUDE status, and describe the association of CP with specific substances among exposed infants. METHOD: This was a retrospective analysis of infants in a high-risk follow-up program (n=5578) between January 2014 and February 2018 with a history of IUDE or who received a CP diagnosis. CP rates were compared using two-sample z-tests. CP classification was assessed using Fisher's exact, Cochran-Armitage, and Wilcoxon rank-sum tests. Models for CP risk were assessed using multivariable logistic regression. RESULTS: Among all infants with IUDE (n=1086), 53.8% were male with a mean (SD) birth gestational age of 36.8 (3.6) weeks. Among unexposed infants with CP (n=259), 54.4% were male with a mean (SD) birth gestational age of 29.9 (5.7) weeks. Opioids were the most common exposure (93.7%) of all infants with IUDE. The CP rate in the IUDE (5.2%) and unexposed (5.7%) high-risk populations were not significantly different (p=0.168), nor were there differences in CP typology, topography, or severity between exposed (n=57) and unexposed (n=259) infants (all p>0.05). In patients with IUDE and after controlling for established CP risk factors, the observed odds of CP varied among substances. INTERPRETATION: We suggest that IUDE should be considered a 'newborn-detectable risk' in the guidelines for the early detection of CP.
AIM: To determine whether infants with intrauterine drug exposure (IUDE) are similarly at risk for cerebral palsy (CP) as other high-risk populations, whether CP classification differs based on IUDE status, and describe the association of CP with specific substances among exposed infants. METHOD: This was a retrospective analysis of infants in a high-risk follow-up program (n=5578) between January 2014 and February 2018 with a history of IUDE or who received a CP diagnosis. CP rates were compared using two-sample z-tests. CP classification was assessed using Fisher's exact, Cochran-Armitage, and Wilcoxon rank-sum tests. Models for CP risk were assessed using multivariable logistic regression. RESULTS: Among all infants with IUDE (n=1086), 53.8% were male with a mean (SD) birth gestational age of 36.8 (3.6) weeks. Among unexposed infants with CP (n=259), 54.4% were male with a mean (SD) birth gestational age of 29.9 (5.7) weeks. Opioids were the most common exposure (93.7%) of all infants with IUDE. The CP rate in the IUDE (5.2%) and unexposed (5.7%) high-risk populations were not significantly different (p=0.168), nor were there differences in CP typology, topography, or severity between exposed (n=57) and unexposed (n=259) infants (all p>0.05). In patients with IUDE and after controlling for established CP risk factors, the observed odds of CP varied among substances. INTERPRETATION: We suggest that IUDE should be considered a 'newborn-detectable risk' in the guidelines for the early detection of CP.
Authors: Iona Novak; Cathy Morgan; Lars Adde; James Blackman; Roslyn N Boyd; Janice Brunstrom-Hernandez; Giovanni Cioni; Diane Damiano; Johanna Darrah; Ann-Christin Eliasson; Linda S de Vries; Christa Einspieler; Michael Fahey; Darcy Fehlings; Donna M Ferriero; Linda Fetters; Simona Fiori; Hans Forssberg; Andrew M Gordon; Susan Greaves; Andrea Guzzetta; Mijna Hadders-Algra; Regina Harbourne; Angelina Kakooza-Mwesige; Petra Karlsson; Lena Krumlinde-Sundholm; Beatrice Latal; Alison Loughran-Fowlds; Nathalie Maitre; Sarah McIntyre; Garey Noritz; Lindsay Pennington; Domenico M Romeo; Roberta Shepherd; Alicia J Spittle; Marelle Thornton; Jane Valentine; Karen Walker; Robert White; Nadia Badawi Journal: JAMA Pediatr Date: 2017-09-01 Impact factor: 16.193
Authors: Dana Olzenak McGuire; Lin H Tian; Marshalyn Yeargin-Allsopp; Nicole F Dowling; Deborah L Christensen Journal: Disabil Health J Date: 2019-01-23 Impact factor: 2.554
Authors: Michael E O'Callaghan; Alastair H MacLennan; Catherine S Gibson; Gai L McMichael; Eric A Haan; Jessica L Broadbent; Paul N Goldwater; Gustaaf A Dekker Journal: Obstet Gynecol Date: 2011-09 Impact factor: 7.661
Authors: Jennifer M McAllister; Eric S Hall; Gayle E R Hertenstein; Stephanie L Merhar; Patricia L Uebel; Scott L Wexelblatt Journal: J Pediatr Date: 2018-05 Impact factor: 4.406
Authors: Elizabeth Allocco; Marjorie Melker; Florencia Rojas-Miguez; Caitlin Bradley; Kristen A Hahn; Elisha M Wachman Journal: Adv Neonatal Care Date: 2016-10 Impact factor: 1.968
Authors: JoAnna K Leyenaar; Andrew P Schaefer; Jared R Wasserman; Erika L Moen; A James O'Malley; David C Goodman Journal: JAMA Pediatr Date: 2021-07-01 Impact factor: 16.193